Back to Search Start Over

miR-150 Suppresses the Proliferation and Tumorigenicity of Leukemia Stem Cells by Targeting the Nanog Signaling Pathway.

Authors :
Xu DD
Zhou PJ
Wang Y
Zhang Y
Zhang R
Zhang L
Chen SH
Fu WY
Ruan BB
Xu HP
Hu CZ
Tian L
Qin JH
Wang S
Wang X
Liu QY
Ren Z
Gu XK
Li YH
Liu Z
Wang YF
Source :
Frontiers in pharmacology [Front Pharmacol] 2016 Nov 18; Vol. 7, pp. 439. Date of Electronic Publication: 2016 Nov 18 (Print Publication: 2016).
Publication Year :
2016

Abstract

Proliferation, a key feature of cancer cells, accounts for the majority of cancer-related diseases resulting in mortality. MicroRNAs (miRNAs) plays important post-transcriptional modulation roles by acting on multiple signaling pathways, but the underlying mechanism in proliferation and tumorigenicity is unclear. Here, we identified the role of miR-150 in proliferation and tumorigenicity in leukemia stem cells (LSCs; CD34+CD38- cells). miR-150 expression was significantly down-regulated in LSCs from leukemia cell lines and clinical samples. Functional assays demonstrated that increased miR-150 expression inhibited proliferation and clonal and clonogenic growth, enhanced chemosensitivity, and attenuated tumorigenic activity of LSCs in vitro . Transplantation animal studies revealed that miR-150 overexpression progressively abrogates tumor growth. Immunohistochemistry assays demonstrated that miR-150 overexpression enhanced caspase-3 level and reduced Ki-67 level. Moreover, luciferase reporter assays indicated Nanog is a direct and functional target of miR-150. Nanog silencing using small interfering RNA recapitulated anti-proliferation and tumorigenicity inhibition effects. Furthermore, miR-150 directly down-regulated the expression of other cancer stem cell factors including Notch2 and CTNNB1. These results provide insights into the specific biological behavior of miR-150 in regulating LSC proliferation and tumorigenicity. Targeting this miR-150/Nanog axis would be a helpful therapeutic strategy to treat acute myeloid leukemia.

Details

Language :
English
ISSN :
1663-9812
Volume :
7
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
27917123
Full Text :
https://doi.org/10.3389/fphar.2016.00439